Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

STAAR Surgical to Participate in Upcoming Investor Conferences: https://mms.businesswire.com/media/20200413005098/en/683092/5/STAAR_Surgical_Logo_Primary_Lockup_%28Sunise_Teal%29.jpg
STAAR Surgical to Participate in Upcoming Investor Conferences


STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that management will participate in several upcoming

Savara Announces New Employment Inducement Grant: https://mms.businesswire.com/media/20200730005071/en/747459/5/SavaraLogo.jpg
Savara Announces New Employment Inducement Grant


Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to three new employees.



On August 3

Chemed Corporation Declares Quarterly Dividend of 40 Cents:
Chemed Corporation Declares Quarterly Dividend of 40 Cents


Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 40-cents per share on the Company’s capital stock, payable on September 5, 2023

Owens & Minor Reports Second Quarter 2023 Financial Results: https://mms.businesswire.com/media/20211103005246/en/922805/5/O%26M_LogoTM_hi-res.jpg
Owens & Minor Reports Second Quarter 2023 Financial Results


Owens & Minor, Inc. (NYSE: OMI) today reported financial results for the second quarter ended June 30, 2023.



Second Quarter Key Highlights:




  • Consolidated revenue of $2.56 billion


  • Net loss

NanoString Technologies Releases Operating Results for Second Quarter of 2023: https://mms.businesswire.com/media/20191104005218/en/753909/5/NSTG-Logo-19-%28002%29.jpg
NanoString Technologies Releases Operating Results for Second Quarter of 2023


NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the second quarter ended June

Xencor Reports Second Quarter 2023 Financial Results: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor Reports Second Quarter 2023 Financial Results


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today

Puma Biotechnology Reports Second Quarter Financial Results: https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology Reports Second Quarter Financial Results


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2023. Unless otherwise stated, all comparisons are for the

Agilent Announces Thought Leader Award to Peter Neubauer: https://unsplash.com/photos/WUehAgqO5hE
Agilent Announces Thought Leader Award to Peter Neubauer


Agilent Technologies Inc. (NYSE: A) announced that Dr. Peter Neubauer has been selected to receive a prestigious Agilent Thought Leader Award. As Chair of Bioprocess Engineering at the Technical

STAAR Surgical Reports Second Quarter 2023 Results: https://mms.businesswire.com/media/20200413005098/en/683092/5/STAAR_Surgical_Logo_Primary_Lockup_%28Sunise_Teal%29.jpg
STAAR Surgical Reports Second Quarter 2023 Results


STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today reported financial results for the second quarter ended June 30, 2023

Sangamo Therapeutics Announces Second Quarter 2023 Conference Call and Webcast: https://mms.businesswire.com/media/20191101005100/en/736004/5/Sangamo_logoTM.jpg
Sangamo Therapeutics Announces Second Quarter 2023 Conference Call and Webcast


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its second quarter 2023 financial results after the market

Charles River Laboratories Expands Access to AAALAC-Accredited, Turnkey Research Space in Key Markets: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories Expands Access to AAALAC-Accredited, Turnkey Research Space in Key Markets


Charles River Laboratories International, Inc. (NYSE: CRL) announced the planned openings of Charles River Accelerator and Development Lab (CRADL®) locations in Seattle and Philadelphia, expanding

Pfizer Reports Second-Quarter 2023 Resultshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Reports Second-Quarter 2023 Results


Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2023. The company narrowed its 2023 revenue guidance(4) range to $67 to $70 billion, while maintaining its outlook for

Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities: https://mms.businesswire.com/media/20191107006076/en/389794/5/navidea_cmyk.jpg
Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities


Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today

Agilent’s 2022 ESG Report Shows Progress Helping Customers Reach Their Sustainability Goals:
Agilent’s 2022 ESG Report Shows Progress Helping Customers Reach Their Sustainability Goals


Agilent Technologies Inc. (NYSE: A) today released its 2022 ESG report on the company’s work supporting customers with their sustainability initiatives while advancing its own internal

Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination: https://mms.businesswire.com/media/20191107006076/en/389794/5/navidea_cmyk.jpg
Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination


Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, received

Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer: https://mms.businesswire.com/media/20191107006076/en/389794/5/navidea_cmyk.jpg
Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer


Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today

Dexcom Reports Second Quarter 2023 Financial Results: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Reports Second Quarter 2023 Financial Results


DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2023.



Second Quarter 2023 Financial Highlights:




  • Revenue grew 25% versus the same

Acadia Healthcare Reports Second Quarter 2023 Results and Raises 2023 Guidance: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Reports Second Quarter 2023 Results and Raises 2023 Guidance


Acadia Healthcare Company, Inc. (“Acadia”) (NASDAQ: ACHC) today announced financial results for the second quarter ended June 30, 2023.



Second Quarter and Recent Highlights




  • Revenue totaled

Xencor to Host Second Quarter 2023 Financial Results Webcast and Conference Call on August 3, 2023: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor to Host Second Quarter 2023 Financial Results Webcast and Conference Call on August 3, 2023


Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will

Novocure Reports Second Quarter 2023 Financial Results: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Reports Second Quarter 2023 Financial Results


Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2023. Novocure is a global oncology company working to extend survival in some of the most aggressive forms

Pfizer Announces Executive Leadership to Advance Oncology Research and Development Strategyhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Announces Executive Leadership to Advance Oncology Research and Development Strategy


Pfizer Inc. (NYSE: PFE) today announced changes to its executive leadership team to further advance its aspirations to discover and develop new medicines and vaccines, with an emphasis on oncology

Chemed Reports Second-Quarter 2023 Results:
Chemed Reports Second-Quarter 2023 Results


Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest

QuidelOrtho Ranks No. 1 in Customer Satisfaction for Six Years in a Row: https://s24.q4cdn.com/594651504/files/design/QO_Logo_FINAL.png
QuidelOrtho Ranks No. 1 in Customer Satisfaction for Six Years in a Row


QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion

Methodist Jennie Edmundson Hospital Partners With Acadia Healthcare to Build New Behavioral Health Hospital in Council Bluffs: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Methodist Jennie Edmundson Hospital Partners With Acadia Healthcare to Build New Behavioral Health Hospital in Council Bluffs


According to American Hospital Directory data, there is a shortfall of more than 300 inpatient behavioral health beds in Iowa and Nebraska.



To address this need, Methodist Jennie Edmundson

Acadia Healthcare Forms Joint Venture Partnership With Nebraska Methodist Health System: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Forms Joint Venture Partnership With Nebraska Methodist Health System


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) announced today that it has formed a joint venture with Nebraska Methodist Health System to build a state-of-the-art, 96-bed behavioral health